SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BEAM, BOL, KERA, LASE, LCAV, LVCI, LZRC, VISX, SNRS, STAA
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bede who wrote (115)5/27/1999 1:36:00 AM
From: yosid   of 253
 
Revenue to the laser manufacturers come from the sale and servicing of the machines, and the fees and royalties that are paid (VISX and BEAM )for use of patented technology.
If vital patents are set aside, it is not only possible that the royalties will decrease, but the competition for laser sales will drive the per unit purchase or lease prices down for new machinery. Massive discounting to gain a foothold into market share is predictable from newly approved laser manufacturers. For them, they must either establish a market, merge with a current player, or die.
Visx is the engine out front for the industry currently (IMHO), and it's legal problems are a drag on not just the hardware producers but the LVC's also. What the market does not seem to grasp is that the LVC's would love to see patent rights die and more (viable) lasers come to market. This represents a chance to access adequate or new technology at less cost with no per/procedure fee. Their interest (LVC's) are more to the inverse of the machine makers.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News